Home Healthcare Healthcare Services AI-Based Clinical Trials Solution Provider Market

AI-Based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report By Therapeutic Applications (Oncology, CVD, Neurological Diseases or Conditions, Metabolic Diseases, Infectious Diseases, Others), By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), By End-User (Pharmaceutical Companies, Academia, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR4575DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. AI-Based Clinical Trials Solution Provider Market, By Therapeutic Applications 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. CVD
    3. Neurological Diseases or Conditions
    4. Metabolic Diseases
    5. Infectious Diseases
    6. Others
  2. AI-Based Clinical Trials Solution Provider Market, By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
    1. Phase-I
    2. Phase-II
    3. Phase-III
  3. AI-Based Clinical Trials Solution Provider Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical Companies
    2. Academia
    3. Others
  4. Regional AI-Based Clinical Trials Solution Provider Market
    1. North America
      1. North America AI-Based Clinical Trials Solution Provider Market By Therapeutic Applications 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
      2. North America AI-Based Clinical Trials Solution Provider Market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase-I
        2. Phase-II
        3. Phase-III
      3. North America AI-Based Clinical Trials Solution Provider Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Academia
        3. Others
      4. U.S.
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      5. Canada
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
    2. Europe
      1. Europe AI-Based Clinical Trials Solution Provider Market By Therapeutic Applications 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
      2. Europe AI-Based Clinical Trials Solution Provider Market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase-I
        2. Phase-II
        3. Phase-III
      3. Europe AI-Based Clinical Trials Solution Provider Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Academia
        3. Others
      4. U.K.
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      5. Germany
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      6. France
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      7. Spain
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      8. Italy
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      9. Russia
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      10. Nordic
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      11. Benelux
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      12. Rest of Europe
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
    3. APAC
      1. APAC AI-Based Clinical Trials Solution Provider Market By Therapeutic Applications 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
      2. APAC AI-Based Clinical Trials Solution Provider Market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase-I
        2. Phase-II
        3. Phase-III
      3. APAC AI-Based Clinical Trials Solution Provider Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Academia
        3. Others
      4. China
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      5. Korea
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      6. Japan
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      7. India
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      8. Australia
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      9. Taiwan
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      10. South East Asia
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      11. Rest of Asia-Pacific
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa AI-Based Clinical Trials Solution Provider Market By Therapeutic Applications 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
      2. Middle East and Africa AI-Based Clinical Trials Solution Provider Market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase-I
        2. Phase-II
        3. Phase-III
      3. Middle East and Africa AI-Based Clinical Trials Solution Provider Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Academia
        3. Others
      4. UAE
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      5. Turkey
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      6. Saudi Arabia
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      7. South Africa
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      8. Egypt
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      9. Nigeria
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      10. Rest of MEA
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
    5. LATAM
      1. LATAM AI-Based Clinical Trials Solution Provider Market By Therapeutic Applications 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
      2. LATAM AI-Based Clinical Trials Solution Provider Market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase-I
        2. Phase-II
        3. Phase-III
      3. LATAM AI-Based Clinical Trials Solution Provider Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Academia
        3. Others
      4. Brazil
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      5. Mexico
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      6. Argentina
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      7. Chile
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      8. Colombia
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
      9. Rest of LATAM
        1. Oncology
        2. CVD
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others
        7. Phase-I
        8. Phase-II
        9. Phase-III
        10. Pharmaceutical Companies
        11. Academia
        12. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.